{
  "author": {
    "name": "Derek Dow",
    "webUrl": "/author/profile/derek-dow/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 1,
    "social": [],
    "articles": [
      {
        "uri": "/2021/10/08/managing-life-sciences-risks-post-pandemic/",
        "title": "Managing life sciences risks post-pandemic",
        "byline": "Derek Dow",
        "kicker": "Analysis",
        "prettyDate": "October 08, 2021",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.propertycasualty360.com/contrib/content/uploads/sites/414/2021/10/Medical-Research-Scientists.jpg-image620x372.jpg",
          "width": "620",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/derek-dow/",
            "name": "Derek Dow"
          }
        ],
        "kickerNode": [
          {
            "uri": "/analysis/",
            "sectionName": "Analysis"
          }
        ],
        "summary": "Lessons from how Canada approached COVID-19 vaccine development could help other markets prepare for industry exposures.",
        "body": null
      }
    ]
  }
}